
From ‘publish or perish' to ‘be visible or vanish': What's next? — Mohammad Tariqur Rahman
To have a higher prestige, the number of papers alone does not suffice. Papers need to be published in journals with high impact factors.
Arguably, the race to increase the number of papers resulted in a number of scientific misconducts, namely, but not limited to, the unethical practice in authorship assignments e.g., guest and honorary authorship; emergence of paper mills; and publishing unauthenticated or manipulated results.
The trend of scientific misconduct has been condemned, yet no practical measures have been taken either to control or to decrease it. Rather, the increasing number of retracted papers every year attest the ongoing 'pandemic' of scientific misconduct. Will the new dictum 'be visible or vanish' then add to the pandemic?
Visibility in academia is generally measured by the number of citations received by the papers of an academic. Indeed, the number of citations increases with the number of publications. However, some may have more citations than others, with less papers. Nevertheless, researching a popular topic increases the chance of higher citations. Self-citation, i.e., when authors cite their own papers, can be monitored by most of the bibliometric databases such as Scopus or Web of Science. However, the practice of self-citation is not acceptable when the authors cite their own papers, especially if they are not relevant and important. Using Scopus records, a PLOS One paper in December 2023 identified Colombia, Egypt, Indonesia, Iran, Italy, Malaysia, Pakistan, Romania, Russia, Saudi Arabia, Thailand, and Ukraine among the top anomalous self-citing countries (i.e., academics from those countries) in the world.
Citing existing literature is an academic norm that reflects the relevance of new research findings, i.e., portrays its rationality, validity, and importance in academic publications. Furthermore, the number of citations provides the impact (and popularity) of the published paper. Albeit, while the 'number' of citations provides the visa for visibility of the paper among the global audience, it does not necessarily represent the paper's importance.
For example, one of the most cited papers (>305,000 in 2014) in the history of academia goes to a paper describing how to quantify proteins in a solution. Even one of the most groundbreaking publications in the field of life science, i.e., the DNA sequencing method (>65000 in 2014) that claimed the Nobel prize and led to complete human genome sequencing, did not have any match to the citation of the protein quantification paper.
Needless to say, a large number of research publications remain behind the curtain without being cited. Former Harvard president Derek Bok, in his book 'Higher Education in America' (published in 2015) noted that a majority of articles published in the arts and humanities (98 per cent) and social sciences (75 per cent) are never cited by another researcher. The current trend is not expected to be very different from this.
A researcher might be interested (or find it important) to research a very rare disease affecting less than 0.1 per cent of the global population. Compared to cancer research, research on such a rare disease will have very low citations. — File pic
That brings an imperative question to answer, does a low (or no) citation make a research less (or not) useful?
Say, a researcher might be interested (or find it important) to research a very rare disease affecting less than 0.1 per cent of the global population. Compared to cancer research, research on such a rare disease will have very low citations. Again, receiving a high number of citations will be unlikely for a research publication addressing a national issue than a global issue. Those two examples suffice to endorse that the number of citations would fail to reflect the importance of research publications. Rather, it would be wrong if citation is used as a measure to evaluate the impact of such research publications.
Going back to the clock, one will find that the dictum 'publish or perish' in academia was introduced in 1942 in Logan Wilson's book, "The Academic Man: A Study in the Sociology of a Profession" - says Eugene Garfield, the founder of Institute for Scientific Information's (ISI). Then, the measurement of journal Impact Factor (IF) was introduced in 1975 by Eugene Garfield as part of the Journal Citation Reports.
Eventually, academics were motivated (read forced) not only to publish more and more papers but also to publish their papers in higher-ranking journals measured by higher IF. Eventually, having a higher number of papers and publishing in the 'high' ranking journals became the requirements in academia for appointment, promotion, and even grant approval. Now, in less than 100 years, academia is experiencing a new survival dictum — be visible or vanish. Amidst the logical criticism, academic policy makers will continue to impose the new dictum for appointment, promotion, and even approval. I wonder if the 'inventors' of new knowledge, i.e., academics at universities, know what is next?
Prof Mohammad is the Deputy Executive Director (Development, Research & Innovation) at International Institute of Public Policy and Management (INPUMA), Universiti Malaya, and can be reached at [email protected]
• This is the personal opinion of the writer or publication and does not necessarily represent the views of Malay Mail.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Free Malaysia Today
a day ago
- Free Malaysia Today
Study attributes 440 ‘excess deaths' to January's Los Angeles wildfires
Additional deaths reflect a mix of factors, from increased exposure to smoke and toxins to healthcare delays and disruptions. (AP pic) LOS ANGELES : Wildfires that devastated parts of the Los Angeles area in January indirectly led to hundreds of deaths in the ensuing weeks, far exceeding the official toll of 31 fatalities, according to a study released on Wednesday. The research, published in the Journal of the American Medical Association, or JAMA, estimated 440 'excess deaths' were attributable to the fires from Jan 5 to Feb 1, using models that compared predicted mortality under normal circumstances to actual numbers documented during that period. The additional deaths likely reflect a mix of factors, including increased exposure of people with heart and lung disease to poor air quality from smoke and toxins released by the fires, as well as healthcare delays and disruptions, the study said. The findings 'underscore the need to complement direct fatalities estimates with alternative methods to quantify the additional mortality burden of wildfires and of climate-related emergencies more broadly,' the researchers wrote. Two wind-driven wildfires that erupted during the first week of January on opposite sides of Los Angeles damaged or destroyed nearly 16,000 structures combined – laying waste to much of the seaside district of Pacific Palisades and the foothill community of Altadena. Together, the blazes scorched 152sq km, an area larger than Paris. The official tally of people who perished as a direct result of the fires stands at 31, after the most recent set of human remains were unearthed in Altadena in July, six months after the fires. Governor Gavin Newsom in February requested nearly US$40 billion in wildfire aid from Congress. Some estimates put economic losses from the fires at more than US$250 billion, making the conflagration one of the most costly natural disasters in US history. The JAMA study acknowledged some limitations, saying the data may need to be revised upward in the future and the research did not reflect any fire-attributable deaths beyond Feb 1.


Malay Mail
4 days ago
- Malay Mail
SpaceX capsule begins 17-hour descent as Crew-10 astronauts head home after nearly five months in orbit
WASHINGTON, Aug 9 — After nearly five months onboard the International Space Station, an international crew of five astronauts began their descent back down to Earth on a SpaceX capsule yesterday. US astronauts Anne McClain and Nichole Ayers, Japan's Takuya Onishi and Russian cosmonaut Kirill Peskov are expected to spend more than 17 hours in the capsule before splashing down off California's coast today. Their return will mark the end of the 10th crew rotation mission to the space station under Nasa's Commercial Crew Program, which was created to succeed the Space Shuttle era by partnering with private industry. The Dragon capsule of billionaire Elon Musk's SpaceX company detached from the International Space Station (ISS) at 2215 GMT on Friday. The capsule's dizzying drop back down to Earth will be slowed when it re-enters Earth -- and then again by huge parachutes to soften its landing. After the capsule splashes down, it will be recovered by a SpaceX ship and hoisted aboard. Only then will the astronauts be able to breathe Earth's air again, for the first time in months. The astronauts, known as Crew-10, conducted numerous scientific experiments during their time on the space station, including studying plant growth and how cells react to gravity. Their launch into space in March was heavily scrutinized because it finally allowed two US astronauts -- who had been unexpectedly stuck onboard the space station for nine months -- to return home. When they launched in June 2024, Butch Wilmore and Suni Williams were only supposed to spend eight days in space on a test of the Boeing Starliner's first crewed flight. However, the spaceship developed propulsion problems and was deemed unfit to fly back, leaving them stranded in space. Nasa announced this week that Wilmore has decided to retire after 25 years of service at the US space agency. Last week, US astronauts Zena Cardman and Mike Fincke, Japan's Kimiya Yui and Russian cosmonaut Oleg Platonov boarded the ISS for a six-month mission.

Malay Mail
6 days ago
- Malay Mail
Covid vaccine patent fight finally ends: Pfizer-BioNTech to pay CureVac and GSK US$740m plus US sales royalties
FRANKFURT, Aug 8 — American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac US$740 million plus royalties to settle US legal disputes over Covid-19 vaccines, CureVac said Friday. The royalties would amount to a 'single-digit' percentage on sales of Covid-19 vaccines in the United States, CureVac said. The German firm added that it would grant Pfizer and BioNTech non-exclusive licence to make and sell mRNA-based Covid and flu products in the United States. GSK, which since 2020 has worked with CureVac to develop mRNA vaccines for infectious diseases, said that it would receive US$370 million as well as a one-per cent royalty on US sales of flu, Covid and 'related combination mRNA vaccine products'. CureVac sued German rival BioNTech in 2022, arguing that BioNTech had infringed patents relating to mRNA technology in making its blockbuster Comirnaty coronavirus vaccine in colloboration with Pfizer. Unlike traditional vaccines which contain some form of the dead or inactivated target virus,mRNA vaccines contain genetic materials that instruct human cells to make proteins typical of the targeted virus. Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than conventional vaccines. The Pfizer-BioNTech vaccine was the first mRNA vaccine approved for use and the first Covid vaccine to receive approval in the West. CureVac's own efforts to make an mRNA-based covid vaccine during the pandemic did not come to fruition. The deal brings the dispute between CureVac and BionNTech to an end ahead of the planned acquisition of CureVac by BioNTech, announced in June. CureVac and BioNTech are still locked in legal disputes in Germany but CureVac said the deal 'set a framework for resolving ongoing patent disputes outside the US'. In March, a German court sided with American pharmaceutical firm Moderna in its claim that BioNTech and Pfizer had broken one of its patents in making its Covid-19 vaccine. — AFP